Database : MEDLINE
Search on : Hla-Dr7 and Antigen [Words]
References found : 336 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 34 go to page                         

  1 / 336 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 28972094
[Au] Autor:Abana CO; Pilkinton MA; Gaudieri S; Chopra A; McDonnell WJ; Wanjalla C; Barnett L; Gangula R; Hager C; Jung DK; Engelhardt BG; Jagasia MH; Klenerman P; Phillips EJ; Koelle DM; Kalams SA; Mallal SA
[Ad] Address:Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232.
[Ti] Title:Cytomegalovirus (CMV) Epitope-Specific CD4 T Cells Are Inflated in HIV CMV Subjects.
[So] Source:J Immunol;199(9):3187-3201, 2017 Nov 01.
[Is] ISSN:1550-6606
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Select CMV epitopes drive life-long CD8 T cell memory inflation, but the extent of CD4 memory inflation is poorly studied. CD4 T cells specific for human CMV (HCMV) are elevated in HIV HCMV subjects. To determine whether HCMV epitope-specific CD4 T cell memory inflation occurs during HIV infection, we used HLA-DR7 (DRB1*07:01) tetramers loaded with the glycoprotein B DYSNTHSTRYV (DYS) epitope to characterize circulating CD4 T cells in coinfected HLA-DR7 long-term nonprogressor HIV subjects with undetectable HCMV plasma viremia. DYS-specific CD4 T cells were inflated among these HIV subjects compared with those from an HIV HCMV HLA-DR7 cohort or with HLA-DR7-restricted CD4 T cells from the HIV-coinfected cohort that were specific for epitopes of HCMV phosphoprotein-65, tetanus toxoid precursor, EBV nuclear Ag 2, or HIV gag protein. Inflated DYS-specific CD4 T cells consisted of effector memory or effector memory-RA subsets with restricted TCRß usage and nearly monoclonal CDR3 containing novel conserved amino acids. Expression of this near-monoclonal TCR in a Jurkat cell-transfection system validated fine DYS specificity. Inflated cells were polyfunctional, not senescent, and displayed high ex vivo levels of granzyme B, CX CR1, CD38, or HLA-DR but less often coexpressed CD38 and HLA-DR The inflation mechanism did not involve apoptosis suppression, increased proliferation, or HIV gag cross-reactivity. Instead, the findings suggest that intermittent or chronic expression of epitopes, such as DYS, drive inflation of activated CD4 T cells that home to endothelial cells and have the potential to mediate cytotoxicity and vascular disease.
[Mh] MeSH terms primary: CD4-Positive T-Lymphocytes/immunology
Cytomegalovirus Infections/immunology
Cytomegalovirus/immunology
Epitopes, T-Lymphocyte/immunology
HIV Infections/immunology
HIV-1/immunology
Viral Proteins/immunology
[Mh] MeSH terms secundary: ADP-ribosyl Cyclase 1/immunology
CD4-Positive T-Lymphocytes/pathology
Cytomegalovirus Infections/pathology
Female
HIV Infections/pathology
HLA-DR7 Antigen/immunology
Humans
Immunologic Memory
Male
Membrane Glycoproteins/immunology
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Epitopes, T-Lymphocyte); 0 (HLA-DR7 Antigen); 0 (Membrane Glycoproteins); 0 (Viral Proteins); EC 3.2.2.5 (CD38 protein, human); EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
[Em] Entry month:1710
[Cu] Class update date: 171116
[Lr] Last revision date:171116
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:171004
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1700851

  2 / 336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28934241
[Au] Autor:Lundgren H; Martinsson K; Cederbrant K; Jirholt J; Mucs D; Madeyski-Bengtson K; Havarinasab S; Hultman P
[Ad] Address:Division of Molecular and Immunological Pathology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Östergötland County Council, Linköping, Sweden.
[Ti] Title:HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity.
[So] Source:PLoS One;12(9):e0184744, 2017.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The oral thrombin inhibitor ximelagatran was withdrawn in the late clinical trial phase because it adversely affected the liver. In approximately 8% of treated patients, drug-induced liver injury (DILI) was expressed as transient alanine transaminase (ALT) elevations. No evidence of DILI had been revealed in the pre-clinical in vivo studies. A whole genome scan study performed on the clinical study material identified a strong genetic association between the major histocompatibility complex alleles for human leucocyte antigens (HLA) (HLA-DR7 and HLA-DQ2) and elevated ALT levels in treated patients. An immune-mediated pathogenesis was suggested. Here, we evaluated whether HLA transgenic mice models could be used to investigate whether the expression of relevant HLA molecules was enough to reproduce the DILI effects in humans. In silico modelling performed in this study revealed association of both ximelagatran (pro-drug) and melagatran (active drug) to the antigen-presenting groove of the homology modelled HLA-DR7 molecule suggesting "altered repertoire" as a key initiating event driving development of DILI in humans. Transgenic mouse strains (tgms) expressing HLA of serotype HLA-DR7 (HLA-DRB1*0701, -DRA*0102), and HLA-DQ2 (HLA-DQB1*0202,-DQA1*0201) were created. These two lines were crossed with a human (h)CD4 transgenic line, generating the two tgms DR7xhCD4 and DQ2xhCD4. To investigate whether the DILI effects observed in humans could be reproduced in tgms, the mice were treated for 28 days with ximelagatran. Results revealed no signs of DILI when biomarkers for liver toxicity were measured and histopathology was evaluated. In the ximelagatran case, presence of relevant HLA-expression in a pre-clinical model did not fulfil the prerequisite for reproducing DILI observed in patients. Nonetheless, for the first time an HLA-transgenic mouse model has been investigated for use in HLA-associated DILI induced by a low molecular weight compound. This study shows that mimicking of genetic susceptibility, expressed as DILI-associated HLA-types in mice, is not sufficient for reproducing the complex pathogenesis leading to DILI in man.
[Mh] MeSH terms primary: Azetidines/toxicity
Benzylamines/toxicity
Chemical and Drug Induced Liver Injury
Disease Models, Animal
HLA-DQ Antigens
HLA-DR7 Antigen
[Mh] MeSH terms secundary: Animals
Cell Line
Chemical and Drug Induced Liver Injury/immunology
Female
HLA-DQ Antigens/genetics
HLA-DQ Antigens/metabolism
HLA-DR7 Antigen/genetics
HLA-DR7 Antigen/metabolism
Humans
Lymphocytes/metabolism
Male
Mice, Inbred C57BL
Mice, Transgenic
Molecular Docking Simulation
Phenotype
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Azetidines); 0 (Benzylamines); 0 (HLA-DQ Antigens); 0 (HLA-DQ2 antigen); 0 (HLA-DR7 Antigen); 49HFB70472 (ximelagatran)
[Em] Entry month:1710
[Cu] Class update date: 171024
[Lr] Last revision date:171024
[Js] Journal subset:IM
[Da] Date of entry for processing:170922
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0184744

  3 / 336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28026046
[Au] Autor:van Sonderen A; Roelen DL; Stoop JA; Verdijk RM; Haasnoot GW; Thijs RD; Wirtz PW; Schreurs MW; Claas FH; Sillevis Smitt PA; Titulaer MJ
[Ad] Address:Department of Neurology, Erasmus University Medical Center, Rotterdam.
[Ti] Title:Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4.
[So] Source:Ann Neurol;81(2):193-198, 2017 Feb.
[Is] ISSN:1531-8249
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Leucine-rich glioma-inactivated1 (LGI1) encephalitis is an antibody-associated inflammation of the limbic area. An autoimmune etiology is suspected but not yet proven. We performed human leukocyte antigen (HLA) analysis in 25 nontumor anti-LGI1 patients and discovered a remarkably strong HLA association. HLA-DR7 was present in 88% compared to 19.6% in healthy controls (p = 4.1 × 10 ). HLA-DRB4 was present in all patients and in 46.5% controls (p = 1.19 × 10 ). These findings support the autoimmune hypothesis. An exploratory analysis was performed in a small group of 4 tumor-LGI1 patients. The strong HLA association seems not applicable in these patients. Therefore, the absence of HLA-DR7 or HLA-DRB4 could raise tumor suspicion in anti-LGI1 patients. Ann Neurol 2017;81:193-198.
[Mh] MeSH terms primary: Encephalitis/genetics
Encephalitis/immunology
HLA-DR7 Antigen/genetics
HLA-DRB4 Chains/genetics
Proteins/immunology
[Mh] MeSH terms secundary: Adult
Aged
Aged, 80 and over
Autoantibodies
Female
Humans
Male
Middle Aged
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Autoantibodies); 0 (HLA-DR7 Antigen); 0 (HLA-DRB4 Chains); 0 (LGI1 protein, human); 0 (Proteins)
[Em] Entry month:1706
[Cu] Class update date: 170630
[Lr] Last revision date:170630
[Js] Journal subset:IM
[Da] Date of entry for processing:161228
[St] Status:MEDLINE
[do] DOI:10.1002/ana.24858

  4 / 336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 27853637
[Au] Autor:Baumgaertner P; Costa Nunes C; Cachot A; Maby-El Hajjami H; Cagnon L; Braun M; Derré L; Rivals JP; Rimoldi D; Gnjatic S; Abed Maillard S; Marcos Mondéjar P; Protti MP; Romano E; Michielin O; Romero P; Speiser DE; Jandus C
[Ad] Address:Ludwig Cancer Research Center, Department of Oncology, University of Lausanne , Switzerland.
[Ti] Title:Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8 and CD4 T-cell responses with multiple specificities including a novel DR7-restricted epitope.
[So] Source:Oncoimmunology;5(10):e1216290, 2016.
[Is] ISSN:2162-4011
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Long synthetic peptides and CpG-containing oligodeoxynucleotides are promising components for cancer vaccines. In this phase I trial, 19 patients received a mean of 8 (range 1-12) monthly vaccines s.c. composed of the long synthetic NY-ESO-1 peptide and CpG-B (PF-3512676), emulsified in Montanide ISA-51. In 18/18 evaluable patients, vaccination induced antigen-specific CD8 and CD4 T-cell and antibody responses, starting early after initiation of immunotherapy and lasting at least one year. The T-cells responded antigen-specifically, with strong secretion of IFNγ and TNFα, irrespective of patients' HLAs. The most immunogenic regions of the vaccine peptide were NY-ESO-1 for CD8 and NY-ESO-1 for CD4 T-cells. We discovered a novel and highly immunogenic epitope (HLA-DR7/NY-ESO-1 ); 7/7 HLA-DR7 patients generated strong CD4 T-cell responses, as detected directly with fluorescent multimers. Thus, vaccination with the long synthetic NY-ESO-1 peptide combined with the strong immune adjuvant CpG-B induced integrated, robust and functional CD8 and CD4 T-cell responses in melanoma patients, supporting the further development of this immunotherapeutic approach.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1611
[Cu] Class update date: 170909
[Lr] Last revision date:170909
[St] Status:PubMed-not-MEDLINE

  5 / 336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 26123672
[Au] Autor:Halfon M; Rotman S; Egli M; Venetz JP; Pascual M
[Ad] Address:University Hospital of Lausanne, University of Lausanne, Lausanne, Switzerland. Matthieu.Halfon@chuv.ch.
[Ti] Title:Continuous subcutaneous insulin pump treatment associated with absence of recurrent kidney allograft diabetic nephropathy.
[So] Source:Acta Diabetol;52(6):1175-7, 2015 Dec.
[Is] ISSN:1432-5233
[Cp] Country of publication:Germany
[La] Language:eng
[Mh] MeSH terms primary: Diabetic Nephropathies/prevention & control
Hypoglycemic Agents/therapeutic use
Insulin Infusion Systems
Insulin/therapeutic use
Kidney Transplantation/adverse effects
[Mh] MeSH terms secundary: Adult
Allografts
Creatinine/blood
Diabetes Mellitus, Type 1/complications
HLA-DR7 Antigen/analysis
Humans
Hypoglycemic Agents/administration & dosage
Insulin/administration & dosage
Male
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (HLA-DR7 Antigen); 0 (Hypoglycemic Agents); 0 (Insulin); AYI8EX34EU (Creatinine)
[Em] Entry month:1612
[Cu] Class update date: 161230
[Lr] Last revision date:161230
[Js] Journal subset:IM
[Da] Date of entry for processing:150701
[St] Status:MEDLINE
[do] DOI:10.1007/s00592-015-0787-z

  6 / 336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 24628273
[Au] Autor:Delgado JF; Amengual MJ; Veraguas A; Rodríguez E; de Los Santos MM; Guallarte MP
[Ad] Address:Immunology Section Laboratory, UDIAT-Centre Diagnòstic, Corporació Sanitària Parc Taulí, Sabadell, Spain; Institut Universitari Parc Taulí-UAB, Universitat Autònoma de Barcelona, Campus d'Excelència Internacional, Bellaterra, Spain.
[Ti] Title:Paediatric celiac patients carrying the HLA-DR7-DQ2 and HLA-DR3-DQ2 haplotypes display small clinical differences.
[So] Source:Acta Paediatr;103(6):e238-42, 2014 Jun.
[Is] ISSN:1651-2227
[Cp] Country of publication:Norway
[La] Language:eng
[Ab] Abstract:AIM: The aim of this study was to determine the relevance of HLA-DR7-DQ2 typing in a prospective cohort of paediatric coeliac disease patients from Southern Europe. METHODS: This cross-sectional study tested 249 paediatric patients with coeliac disease. HLA-DR3-DQ2 was typed in combination with HLA-DR7-DQ2 to screen for the HLA-DQ2 haplotype. The histological, analytical and clinical characteristics of the subjects were recorded. RESULTS: A total of 91 coeliac patients were diagnosed: 96.7% carried HLA-DQ2 and 4.4% carried HLA-DQ8. In percentage terms, 80.2% of patients carried HLA-DR3-DQ2 and 34.1% carried HLA-DR7-DQ2. We did not find significant differences between HLA-DR7-DQ2 and HLA-DR3-DQ2 paediatric patients with respect to histological damage and clinical characteristics, except for irritability and weight loss. These characteristics were more frequent in HLA-DQ2trans than in HLA-DQ2cis (22.2% vs. 0.0% [p = 0.035] and 55.6% vs. 21.4% [p = 0.017], respectively). Coeliac-specific autoantibody levels were higher in HLA-DQ2cis than one half of HLA-DQ2trans patients (105.5 vs. 19.2 U/mL, p = 0.014). CONCLUSION: Small clinical differences were found between paediatric coeliac patients carrying HLA-DR7-DQ2 and HLA-DR3-DQ2. For a correct screening of HLA-DQ2, at least in our geographical population, the HLA-DR7-DQ2 haplotype should be typed due to its frequency and clinical presentation.
[Mh] MeSH terms primary: Celiac Disease/genetics
HLA-DQ Antigens/genetics
HLA-DR3 Antigen/genetics
HLA-DR7 Antigen/genetics
[Mh] MeSH terms secundary: Chi-Square Distribution
Child
Cross-Sectional Studies
Europe
Female
Genetic Testing
Haplotypes
Humans
Immunity, Humoral/genetics
Male
Pediatrics
Polymerase Chain Reaction
Prospective Studies
Statistics, Nonparametric
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (HLA-DQ Antigens); 0 (HLA-DQ8 antigen); 0 (HLA-DR3 Antigen); 0 (HLA-DR7 Antigen)
[Em] Entry month:1501
[Cu] Class update date: 140509
[Lr] Last revision date:140509
[Js] Journal subset:IM
[Da] Date of entry for processing:140318
[St] Status:MEDLINE
[do] DOI:10.1111/apa.12605

  7 / 336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 23421483
[Au] Autor:Heide G; Stuge TB; Skogen B; Husebekk A; Ahlen MT
[Ti] Title:The DR7-DQ2 haplotype in a native Norwegian population.
[So] Source:Scand J Immunol;77(5):429-30, 2013 May.
[Is] ISSN:1365-3083
[Cp] Country of publication:England
[La] Language:eng
[Mh] MeSH terms primary: HLA-DQ Antigens/genetics
HLA-DQ beta-Chains/genetics
HLA-DR7 Antigen/genetics
HLA-DRB1 Chains/genetics
[Mh] MeSH terms secundary: Alleles
Gene Frequency
Haplotypes
Humans
Norway
[Pt] Publication type:LETTER
[Nm] Name of substance:0 (HLA-DQ Antigens); 0 (HLA-DQ beta-Chains); 0 (HLA-DQ2 antigen); 0 (HLA-DQB1 antigen); 0 (HLA-DR7 Antigen); 0 (HLA-DRB1 Chains)
[Em] Entry month:1307
[Cu] Class update date: 130424
[Lr] Last revision date:130424
[Js] Journal subset:IM
[Da] Date of entry for processing:130221
[St] Status:MEDLINE
[do] DOI:10.1111/sji.12031

  8 / 336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 23225889
[Au] Autor:Eljaafari A; Yuruker O; Ferrand C; Farre A; Addey C; Tartelin ML; Thomas X; Tiberghien P; Simpson E; Rigal D; Scott D
[Ad] Address:Etablissement Français du Sang Rhone Alpes, HLA Department, Lyon 69007, France. assia.eljaafari@univ-lyon1.fr
[Ti] Title:Isolation of human CD4/CD8 double-positive, graft-versus-host disease-protective, minor histocompatibility antigen-specific regulatory T cells and of a novel HLA-DR7-restricted HY-specific CD4 clone.
[So] Source:J Immunol;190(1):184-94, 2013 Jan 01.
[Is] ISSN:1550-6606
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Minor histocompatibility (H) Ags are classically described as self-peptides derived from intracellular proteins that are expressed at the cell surface by MHC class I and class II molecules and that induce T cell alloresponses. We have isolated three different T cell populations from a skin biopsy of a patient suffering from acute graft-versus-host disease following sex-mismatched HLA-identical bone marrow transplantation. The first population was: 1) CD4(+)/CD8(+) double-positive; 2) specific for an HLA class I-restricted autosomal Ag; 3) expressed a Tr1 profile with high levels of IL-10, but low IL-2 and IFN-γ; and 4) exerted regulatory function in the presence of recipient APCs. The second was CD8 positive, specific for an HLA class I-restricted autosomally encoded minor H Ag, but was only weakly cytotoxic. The third was CD4 single positive, specific for an HLA-DR7-restricted HY epitope and exerted both proliferative and cytotoxic functions. Identification of the peptide recognized by these latter cells revealed a new human HY epitope, TGKIINFIKFDTGNL, encoded by RPS4Y and restricted by HLA-DR7. In this paper, we show human CD4/CD8 double-positive, acute graft-versus-host disease-protective, minor H Ag-specific regulatory T cells and identify a novel HLA-DR7/ HY T cell epitope, encoded by RPS4Y, a potential new therapeutic target.
[Mh] MeSH terms primary: CD4-Positive T-Lymphocytes/immunology
CD8-Positive T-Lymphocytes/immunology
Epitopes, T-Lymphocyte/immunology
Graft vs Host Disease/prevention & control
H-Y Antigen/immunology
HLA-DR7 Antigen/genetics
Minor Histocompatibility Antigens/immunology
T-Lymphocytes, Regulatory/immunology
[Mh] MeSH terms secundary: Antigen Presentation/immunology
CD4-Positive T-Lymphocytes/cytology
CD4-Positive T-Lymphocytes/metabolism
CD8-Positive T-Lymphocytes/cytology
CD8-Positive T-Lymphocytes/metabolism
Cell Line, Transformed
Cell Separation/methods
Clone Cells
Female
Graft vs Host Disease/immunology
Graft vs Host Disease/pathology
HLA-DRB1 Chains/genetics
Humans
Male
Minor Histocompatibility Antigens/metabolism
T-Lymphocytes, Regulatory/cytology
T-Lymphocytes, Regulatory/metabolism
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Epitopes, T-Lymphocyte); 0 (H-Y Antigen); 0 (HLA-DR7 Antigen); 0 (HLA-DRB1 Chains); 0 (Minor Histocompatibility Antigens)
[Em] Entry month:1303
[Cu] Class update date: 121224
[Lr] Last revision date:121224
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:121211
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1201163

  9 / 336 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Clinical Trials Registry
Full text

[PMID]: 23042966
[Au] Autor:Höcker B; Fickenscher H; Delecluse HJ; Böhm S; Küsters U; Schnitzler P; Pohl M; John U; Kemper MJ; Fehrenbach H; Wigger M; Holder M; Schröder M; Billing H; Fichtner A; Feneberg R; Sander A; Köpf-Shakib S; Süsal C; Tönshoff B
[Ad] Address:University Children's Hospital, Im Neuenheimer Feld 430, D-69120 Heidelberg, Germany.
[Ti] Title:Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study.
[So] Source:Clin Infect Dis;56(1):84-92, 2013 Jan.
[Is] ISSN:1537-6591
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: The epidemiology and morbidity of Epstein-Barr virus (EBV) infection in pediatric renal transplant recipients have been characterized insufficiently. METHODS: In a prospective, multicenter study among 106 pediatric kidney allograft recipients aged 11.4 ± 5.9 years, we investigated the epidemiology of EBV infection and the relationship between EBV load, EBV serology, and EBV-related morbidity (posttransplant lymphoproliferative disease [PTLD] or symptomatic EBV infection, defined as flu-like symptoms or infectious mononucleosis). RESULTS: EBV primary infection occurred in 27 of 43 (63%) seronegative patients and reactivation/reinfection in 28 of 63 (44%) seropositive patients. There was no association between the degree or duration of EBV load and EBV-related morbidity: The vast majority (17 of 18 [94%]) of patients with a high, persistent EBV load remained PTLD-free throughout a follow-up of 5.0 ± 1.3 years, while 2 of 3 (66%) patients with EBV-related PTLD exhibited only a low EBV load beforehand. Eight of 18 (44%) patients with a high, persistent EBV load remained asymptomatic during a follow-up of 5.3 ± 2.9 years. Multivariate analysis identified the EBV high-risk (D(+)/R(-)) serostatus (odds ratio [OR], 7.07; P < .05), the presence of human leukocyte antigen (HLA)-DR7 (OR, 5.65; P < .05), and the intensity of the immunosuppressive therapy (OR, 1.53; P < .01) as independent risk factors for the development of a symptomatic EBV infection. CONCLUSIONS: Presence of EBV high-risk seroconstellation, HLA-DR7, and intensity of immunosuppressive therapy are significant risk factors for a symptomatic EBV infection, whereas there is no close association between the degree or duration of EBV load and EBV-related morbidity. Clinical Trials Registration. NCT00963248.
[Mh] MeSH terms primary: Epstein-Barr Virus Infections/epidemiology
Herpesvirus 4, Human/isolation & purification
Kidney Transplantation/statistics & numerical data
[Mh] MeSH terms secundary: Adolescent
Analysis of Variance
Antiviral Agents/therapeutic use
Child
Epstein-Barr Virus Infections/immunology
Epstein-Barr Virus Infections/therapy
Epstein-Barr Virus Infections/virology
Female
Graft Rejection/drug therapy
Graft Rejection/prevention & control
Herpesvirus 4, Human/immunology
Humans
Immunosuppressive Agents/therapeutic use
Lymphoproliferative Disorders/epidemiology
Lymphoproliferative Disorders/etiology
Lymphoproliferative Disorders/virology
Male
Morbidity
Prospective Studies
Statistics, Nonparametric
Transplants/statistics & numerical data
Viral Load
[Pt] Publication type:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Antiviral Agents); 0 (Immunosuppressive Agents)
[Em] Entry month:1306
[Cu] Class update date: 121211
[Lr] Last revision date:121211
[Js] Journal subset:IM
[Da] Date of entry for processing:121009
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1093/cid/cis823

  10 / 336 MEDLINE  
              first record previous record
select
to print
Photocopy

[PMID]: 23469632
[Au] Autor:Hussein EM; Al-Mohammed HI; Al-Mulhim AS; Aboulmagd E
[Ad] Address:Department of Medical Parasitology, Faculty of Medicine, University of Suez Canal, Ismailia, King Fisal, AI-Ahsa, Egypt.
[Ti] Title:HLA class II DRB1 resistance and susceptible markers in hydatidosis Saudi patients in association to the clinical course and gender.
[So] Source:J Egypt Soc Parasitol;42(3):573-82, 2012 Dec.
[Is] ISSN:1110-0583
[Cp] Country of publication:Egypt
[La] Language:eng
[Ab] Abstract:Hydatidosis constitutes a major public health problem in kingdom of Saudi Arabia. The variability on susceptibility to hydatidosis has been related to the HLA system. So this study aimed to identifying the possible association between the class-II HLA-DRB1 alleles with the occurrence of hydatidosis and the clinical course in Saudi patients using Micro SSP HLA-DRB1 kits. Since HLA-disease associations might vary in relation to gender, so this study aims also to determining the HLA-DRB1 alleles- hydatidosis association in relation to gender. The results proved that HLA-DR16 and HLA-DR7 alleles were the suitable markers of susceptibility association while HLA-DR1 and HLA-DR10 alleles might confer protection against hydatidosis. All the previous susceptible and resistance associations were statistically significant. Also, the majority of the female patients (81.8%) had HLA-DR14 compared to 9.1% of female controls while 50% of the male patients had HLA-DR7 compared to 4.5% of male controls. These results were statistically associated and this is the first study that found an association between certain HLA-DRB 1 alleles and the occurrence of human hydatidosis in relation to gender. Also, significant relations were detected between HLA-DR16 and hepatic and single cyst, HLA-DR7 and lung cyst, HLA-DR14 and combined cysts. Also, no statistical significance was found between other cystic characteristics and any one of the susceptible HLA-DRBs. On conclusion beside the role HLA-DRB 1 on the susceptibility or the resistance to hydatidosis disease occurrence among Saudi population also it may have an important role in the prevalence of the disease in relation to gender.
[Mh] MeSH terms primary: Echinococcosis/immunology
HLA-DR beta-Chains/genetics
[Mh] MeSH terms secundary: Adolescent
Adult
Alleles
Case-Control Studies
Child
DNA/chemistry
DNA/isolation & purification
Disease Resistance/genetics
Echinococcosis/epidemiology
Female
Genetic Markers
Genetic Predisposition to Disease/genetics
Genotyping Techniques
HLA-DR beta-Chains/classification
Humans
Male
Prevalence
Saudi Arabia/epidemiology
Sex Factors
Young Adult
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Genetic Markers); 0 (HLA-DR beta-Chains); 9007-49-2 (DNA)
[Em] Entry month:1404
[Cu] Class update date: 130308
[Lr] Last revision date:130308
[Js] Journal subset:IM
[Da] Date of entry for processing:130309
[St] Status:MEDLINE


page 1 of 34 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information